The Development of Non-Invasive Diagnostic Tools in Bladder Cancer

Schulz, Alison E.; Loloi, Justin; Martina, Luis Pina; Sankin, Alexander

doi:10.2147/ott.s283891

Cited by 13 publications

(10 citation statements)

References 71 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various isolation, extraction, detection and analysis methods are available and used interchangeably for all different analytes. An interesting innovation in this field is the development of microfluidic methods to aid in the separation and detection of certain analytes, 236 with test cases already available for bladder, 237 prostate 238 and gastric 239 cancer.…”

Section: Future Considerations and Recommendationsmentioning

confidence: 99%

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Jordaens

Zwaenepoel

Tjalma

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of this review was to explore the status of urine sampling as a liquid biopsy for noninvasive cancer research by reviewing used preanalytical parameters and protocols.We searched two main health sciences databases, PubMed and Web of Science. From all eligible publications (2010-2022), information was extracted regarding: (a) study population characteristics, (b) cancer type, (c) urine preanalytics, (d) analyte class, (e) isolation method, (f ) detection method, (g) comparator used, (h) biomarker type, (i) conclusion and (j) sensitivity and specificity. The search query identified 7835 records, of which 924 unique publications remained after screening the title, abstract and full text. Our analysis demonstrated that many publications did not report information about the preanalytical parameters of their urine samples, even though several other studies have shown the importance of standardization of sample handling. Interestingly, it was noted that urine is used for many cancer types and not just cancers originating from the urogenital tract. Many different types of relevant analytes have been shown to be found in urine. Additionally, future considerations and recommendations are discussed: (a) the heterogeneous nature of urine, (b) the need for standardized practice protocols and (c) the road toward the clinic. Urine is an emerging liquid biopsy with broad applicability in different analytes and several cancer types. However, standard

show abstract

Section: Future Considerations and Recommendationsmentioning

confidence: 99%

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Jordaens

Zwaenepoel

Tjalma

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…7 BTA-Stat is a point-of-care rapid immunochromatographic assay that provides results within 5 min, while BTA-TRAK is an enzymelinked immunosorbent assay (ELISA) assay. 8 In Japan, urinary qualitative BTA test is approved in a surveillance setting. BTA assays detect and measure the presence of human complement factor H-related proteins (hCFHrp) in urine.…”

Section: Protein-based Urinary Markermentioning

confidence: 99%

Urinary markers for bladder cancer diagnosis: A review of current status and future challenges

Tomiyama,

Fujita,

Hashimoto

et al. 2023

Int J of Urology

View full text Add to dashboard Cite

Bladder cancer is a common urological cancer with a high recurrence rate that requires long‐term follow‐up, and early detection positively affects prognosis. To date, the initial diagnosis and follow‐up for bladder cancer rely on cystoscopy, which is an invasive and expensive procedure. Therefore, urinary markers for the detection of bladder cancer have attracted research attention for decades to reduce unnecessary cystoscopies. Urine, which is in continuous contact with bladder cancer, is considered a suitable fluid for providing tumor information. Urinary cytology is the only widely used urinary marker in clinical practice; however, it has poor sensitivity for low‐grade tumors; indicating the need for novel urinary markers. Considerable research has been conducted on this topic over the years, resulting in a complex landscape with a wide range of urinary markers, including protein‐, exfoliated cell‐, RNA‐, DNA‐, and extracellular vesicle‐based markers. Although some of these markers have been approved by the U.S. Food and Drug Administration and are commercially available, their use in clinical practice is limited. To facilitate clinical application, potential urinary markers must withstand prospective clinical trials and be easy for patients and clinicians to understand and utilize in a clinical context. This review provides a comprehensive overview of currently available and recently reported promising urinary markers for bladder cancer. Additionally, the challenges and the prospects of these urinary markers for clinical implementation in bladder cancer treatment were discussed.

show abstract

“…Urinary tract cancers (UTCs) such as bladder and prostate cancers, as well as renal cell carcinoma are among the most malignant tumors and associated with high morbidity and mortality. – Current routine approaches for the detection and monitoring of UTCs rely on a combined evidence of histopathological and imaging features of tumor tissues, which is typically invasive and not affordable to populations especially in low-resource settings . Alternatively, standard biopsy testing for UTCs is performed via the identification of specific circulating tumor cells or extracellular vesicles in the bloodstream.…”

Section: Introductionmentioning

confidence: 99%

Rapid Diagnosis of Urinary Tract Cancers on a LEGO-Inspired Detection Platform via Chemiresistive Profiling of Volatile Metabolites

Sun,

Liu,

Liu

et al. 2023

Anal. Chem.

View full text Add to dashboard Cite

Rapid and in situ profiling of volatile metabolites from body fluids represents a new trend in cancer diagnosis and classification in the early stages. We report herein an on-chip strategy that combines an array of conductive nanosensors with a chaotic gas micromixer for real-time monitoring of volatiles from urine and for accurate diagnosis and classification of urinary tract cancers. By integrating a class of LEGO-inspired microchambers immobilized with MXene-based sensing nanofilms and zigzag microfluidic gas channels, it enables the intensive intermingling of volatile organic chemicals with sensor elements that tremendously facilitate their ion−dipole interactions for molecular recognition. Aided with an allin-one, point-of-care platform and an effective machine-learning algorithm, healthy or diseased samples from subpopulations (i.e., tumor subtypes, staging, lymph node metastasis, and distant metastasis) of urinary tract cancers can be reliably fingerprinted in a few minutes with high sensitivity and specificity. The developed detection platform has proven to be a noninvasive supplement to the liquid biopsies available for facile screening of urinary tract cancers, which holds great potential for large-scale personalized healthcare in low-resource areas.

show abstract

The Development of Non-Invasive Diagnostic Tools in Bladder Cancer

Cited by 13 publications

References 71 publications

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Urinary markers for bladder cancer diagnosis: A review of current status and future challenges

Rapid Diagnosis of Urinary Tract Cancers on a LEGO-Inspired Detection Platform via Chemiresistive Profiling of Volatile Metabolites

Contact Info

Product

Resources

About